Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Jan;4(1):55-9.
doi: 10.1159/000324487. Epub 2011 Feb 5.

Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature

M Delgado  1 , E Pérez-Ruiz, J Alcalde, D Pérez, R Villatoro, A Rueda
Affiliations
Case Reports

Anti-angiogenic treatment (sunitinib) for disseminated malignant haemangiopericytoma: a case study and review of the literature

M Delgado et al. Case Rep Oncol. 2011 Jan.

Abstract

Introduction: A meningeal haemangiopericytoma (HP) is a mesenchymal tumour that makes up less than 1% of all CNS tumours. HPs arise from pericytes and present high rates of recurrence and distant metastasis. The primary treatment option is surgery. When the disease is disseminated, chemotherapy produces a weak and short-lived response; therefore, new drugs are needed.

Case presentation: We describe the case of a 65-year-old woman with a 13-year history of recurrent HP. After local treatment with radiotherapy, she developed metastases that required systemic treatment, and treatment with sunitinib, an oral inhibitor of the vascular endothelial growth factor receptor and the platelet-derived growth factor receptor, was initiated. As a result, radiological stabilisation of the systemic disease was maintained for over 12 months.

Conclusions: Anti-angiogenic agents can be useful for treating disseminated HP, but further studies are needed to confirm their possible role in controlling metastatic disease.

Keywords: Haemangiopericytoma; Platelet-derived growth factor receptor; Sunitinib Vascular endothelial growth factor receptor.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Metastatic hepatic lesion in segment 3 measuring 38 mm before treatment with sunitinib. April 2009.
Fig. 2.
Fig. 2.
Metastatic hepatic lesion in segment 3 measuring 30 mm after treatment with sunitinib. May 2010.
See this image and copyright information in PMC

References

    1. Mena H, Ribus JL, Pezeshkpour GH, et al. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol. 1991;22:84–91. - PubMed
    1. Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989;25:514–522. - PubMed
    1. Dufour H, Métellus P, Fuentes S, et al. Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery. 2001;48:756–762. discussion 762-763. - PubMed
    1. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. Cancer. 1998;82:1915–1920. - PubMed
    1. Wong P, Yagoda A. Chemotherapy of malignant hemangiopericytoma. Cancer. 1978;41:1256–1260. - PubMed

Publication types